Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DaRT and Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT05047094Recruiting
- Sponsor
- Alpha Tau Medical Ltd.
- Start
- Nov 2021
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Alpha Tau Medical Ltd. Primary endpoint: Evaluation of Efficacy of DaRT Treatment in Combination with Pembrolizumab. Started Nov 2021; status: recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05047094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05047094.